Lorazepam study points to fewer repeat blockages in male cats: full analysis

A newly published randomized, placebo-controlled study in JAVMA points to lorazepam as a possible way to reduce repeat urethral obstruction in male cats after an initial hospitalization. The study, “Lorazepam reduces recurrence of urethral obstruction in male cats,” was published online in May 2026 and evaluated 80 client-owned male cats presenting with urethral obstruction at a university teaching hospital from 2021 through 2025. Available online summaries indicate the recurrence rate was 15.7% in the placebo group and 0% in the lorazepam group. (consultant.vet.cornell.edu)

That finding matters because feline urethral obstruction is common, painful, and expensive to manage, and recurrence is a major driver of repeat emergency visits, client distress, and, in some cases, euthanasia. It is also a true medical emergency: as the study author noted in an AVMA Veterinary Vertex discussion, obstructed cats can rapidly develop severe hyperkalemia, acidosis, and life-threatening cardiac arrhythmias, with progression to bladder rupture, uroabdomen, acute kidney injury, and death if treatment is delayed. Background literature has long described recurrence as a persistent problem, with published estimates often falling around 15% to 40%, depending on case selection and follow-up. Reviews and clinical guidance have also emphasized that many obstructed male cats do not have a fixed mechanical blockage, but a combination of inflammation, plugs, edema, and functional urethral spasm. (pubmed.ncbi.nlm.nih.gov)

That context is important because the profession has been here before with other adjunct drugs. Evidence around prazosin, for example, has been inconsistent, and a 2023 evidence review concluded there is not enough high-quality evidence to say it reduces recurrent obstruction in male cats. In other words, clinicians have had plausible pharmacologic options, but not much definitive trial data showing that one clearly changes outcomes after discharge. The Veterinary Vertex interview adds useful context here: the investigators framed the project as part of a broader effort to answer unresolved questions not just about stabilization and etiology, but about how to prevent recurrence of this life-threatening condition after the initial crisis has passed. (ivis.org)

The new lorazepam study appears designed to address that gap more rigorously. According to the abstract metadata and article listings available online, it was prospective, randomized, double-blinded, and placebo-controlled, and it focused on first-time urethral obstruction cases while excluding cats with urolithiasis or urinary tract infection. Those exclusions matter, because they narrow the population to cats more likely to have idiopathic or functional obstruction mechanisms, where anxiolysis and muscle relaxation could plausibly help. In the Veterinary Vertex discussion, the study author also reviewed the typical causes of obstruction, noting that urethral plugs made up of mucus, protein matrix, inflammatory material, and sometimes crystalline debris such as struvite are the most common cause, while stones and neoplasia are less common. The author list includes investigators affiliated with the University of Minnesota’s urology and nephrology ecosystem, including Jody Lulich, whose work has long focused on feline urinary disease. (ablesci.com)

Direct expert reaction to this specific paper was limited in accessible public sources at the time of writing, but the broader field has repeatedly highlighted the need for better recurrence prevention. Clinical resources from referral and academic centers describe urethral obstruction as a true emergency in male cats and note that post-obstructive management often includes pain control, hydration, diet changes, environmental modification, and medications aimed at reducing urethral spasm or stress. This new study is likely to draw attention because it offers something the field has wanted for years: randomized evidence that a discharge medication may actually reduce repeat blockage. (vetmed.illinois.edu)

Why it matters: For veterinary professionals, the practical question is whether lorazepam should change discharge protocols now or simply prompt closer review. The answer is probably somewhere in between. The reported effect size is striking, but the study population was specific: first-time male cats, treated at a teaching hospital, with urolithiasis and UTI excluded. That means general practices and ER teams should be careful not to overgeneralize the result to all blocked cats, especially recurrent cases, cats with stones, or cats with concurrent disease. Still, the biologic rationale is stronger than it may first appear. In cats whose obstruction is driven less by a fixed lesion and more by plugs, inflammation, edema, stress, and urethral spasm, a drug with anxiolytic and muscle-relaxant effects could reasonably reduce the risk of re-obstruction in the vulnerable post-catheter period. If the full paper confirms acceptable tolerability, clear dosing guidance, and clinically meaningful follow-up, lorazepam could become an important addition to medical management in selected cases. (ablesci.com)

There’s also a larger signal here about how the profession is thinking about blocked cats. Recent educational and clinical materials increasingly frame recurrence prevention as more than a catheter problem. Stress biology, pain, urethral spasm, and home management all play a role. A drug that works through anxiolytic and muscle-relaxant effects would fit that broader shift, especially for cats whose obstruction is tied to feline idiopathic cystitis-like disease rather than a removable stone burden. That is an inference from the disease model, the study’s exclusion criteria, and the author’s discussion of common plug-based and functional causes of obstruction, but it is a reasonable one. (pubmed.ncbi.nlm.nih.gov)

What to watch: Next, watch for the full-text paper to circulate more widely, for conference discussion or journal clubs to pressure-test the methods, and for follow-up studies to answer the remaining questions: optimal dose and duration, sedation risk in the home setting, benefit in recurrent cases, and whether the effect persists in broader practice populations. It will also be worth watching whether this study pushes more clinicians to think about recurrence prevention as a combined medical and behavioral problem, not just a mechanical one. If those answers are favorable, lorazepam may move quickly from interesting paper to meaningful protocol change in feline emergency and primary care medicine. (consultant.vet.cornell.edu)